Furthermore, increased HER-2 expression was an independent risk factor for recurrence-free survival (RFS) in patients (<i>p</i> < 0.01, HR = 3.421); Conclusions: The increased expression of HER-2 and its relationship with immune cells will provide new insights for immunotherapy in CRC patients. The gene discussed is ERBB2; the disease is colorectal carcinoma.